Matching articles for "antiseizure medications"
Issue 1709 · August 19, 2024
Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder (online only)

The FDA has approved ganaxolone ( Ztalmy – Marinus) for oral treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients ≥2 years old. It is the first drug…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):e139-40 doi:10.58347/tml.2024.1709g
The FDA has approved ganaxolone ( Ztalmy – Marinus) for oral treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients ≥2 years old. It is the first drug to be approved in the US for this indication.
Issue 1708 · August 5, 2024
Drugs for Epilepsy

When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of…

Med Lett Drugs Ther. 2024 Aug 5; 66(1708):121-8 doi:10.58347/tml.2024.1708a
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally try at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time.
Issue 1679 · June 26, 2023
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia

The FDA has approved the oral second-generation antipsychotic drug brexpiprazole ( Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated with dementia due to Alzheimer's disease (AD).…

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):99-101 doi:10.58347/tml.2023.1679b
The FDA has approved the oral second-generation antipsychotic drug brexpiprazole ( Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated with dementia due to Alzheimer's disease (AD). Brexpiprazole is the first drug to be approved in the US for this indication. It is also approved for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder.
Issue 1678 · June 12, 2023
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

View the Comparison Table: Some Drugs for Migraine Prevention in Adults

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):e100-2 doi:10.58347/tml.2023.1678c
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Issue 1678 · June 12, 2023 Free
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):89-96 doi:10.58347/tml.2023.1678a
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1645 · March 7, 2022
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive…

Med Lett Drugs Ther. 2022 Mar 7; 64(1645):33-40
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Issue 1608 · October 5, 2020
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2020 Oct 5; 62(1608):153-60
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1605 · August 24, 2020
Cenobamate (Xcopri) for Focal Seizures

The FDA has approved cenobamate ( Xcopri – SK Life Science) for oral treatment of partial-onset (focal) seizures in adults.

Med Lett Drugs Ther. 2020 Aug 24; 62(1605):134-6
The FDA has approved cenobamate ( Xcopri – SK Life Science) for oral treatment of partial-onset (focal) seizures in adults.
Issue 1596 · April 20, 2020
Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Clusters

The FDA has approved nasal spray formulations of the benzodiazepines diazepam ( Valtoco — Neurelis) and midazolam ( Nayzilam — UCB) for acute treatment of intermittent episodes of frequent seizure activity…

Med Lett Drugs Ther. 2020 Apr 20; 62(1596):63-4
The FDA has approved nasal spray formulations of the benzodiazepines diazepam ( Valtoco — Neurelis) and midazolam ( Nayzilam — UCB) for acute treatment of intermittent episodes of frequent seizure activity (seizure clusters). Diazepam rectal gel ( Diastat, Diastat AcuDial , and generics) has been used for this indication for many years.